Angiotensin-Converting Enzyme Inhibitors and Risk of Esophageal and Gastric Cancer: A Nested Case-Control Study

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 10, 2007, Pages

  Sjöberg, Tomas ^a   García Rodríguez, Luis A ^b   Lindblad, Mats ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Department of Pharmacoepidemiology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; UNITED KINGDOM;

EID: 34748850313     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.08.005     Document Type: Article

References (17)

1. Ino K., Shibata K., Kajiyama H., et al. Manipulating the angiotensin system-new approaches to the treatment of solid tumours. Expert Opin Biol Ther 6 (2006) 243-255
2. Achard J.M., Pruna A., Fernandez L.A., et al. Prevention of stroke and cancer: could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?. Am J Hypertens 12 (1999) 1050-1053
3. Smith G.R., and Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond) 1 (2004) 3
4. Egami K., Murohara T., Shimada T., et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112 (2003) 67-75
5. Herbst R.S., Hidalgo M., Pierson A.S., et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 29 (2002) 66-77
6. Lever A.F., Hole D.J., Gillis C.R., et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 352 (1998) 179-184
7. Lindholm L.H., Anderson H., Ekbom T., et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358 (2001) 539-544
8. Friis S., Sorensen H.T., Mellemkjaer L., et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92 (2001) 2462-2470
9. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37 Suppl 8 (2001) S4-S66
10. Garcia Rodriguez G. Use of the UK general practice research data base for pharmacoepidemiology. Br J Clin Pharmacol 45 (1998) 415-419
11. Jick S.S., Kaye J.A., Vasilakis-Scaramozza C., et al. Validity of the general practice research database. Pharmacotherapy 23 (2003) 686-689
12. Lindblad M., Lagergren J., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 444-450
13. Jansson C., Johansson A.L., Nyren O., et al. Socioeconomic factors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study. Cancer Epidemiol Biomarkers Prev 14 (2005) 1754-1761
14. Terry P.D., Lagergren J., Wolk A., et al. Dietary intake of heterocyclic amines and cancers of the esophagus and gastric cardia. Cancer Epidemiol Biomarkers Prev 12 (2003) 940-944
15. Lagergren J., Ye W., Lindgren A., et al. Heredity and risk of cancer of the esophagus and gastric cardia. Cancer Epidemiol Biomarkers Prev 9 (2000) 757-760
16. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 18 (1999) 825-831
17. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70